AMG 701 Expanded Access Program
- Registration Number
- NCT05256446
- Lead Sponsor
- Amgen
- Brief Summary
Expanded access requests for AMG 701 may be considered for adult patients with relapsed and/or refractory multiple myeloma whose disease is in partial response or better after AMG 420 therapy. To request access, use Responsible Party contact information provided in this record.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie AMG 701's activity in relapsed/refractory multiple myeloma patients post-AMG 420 therapy?
How does AMG 701 compare to standard-of-care treatments for multiple myeloma in terms of efficacy and safety profiles?
What biomarkers are associated with response prediction in AMG 701 expanded access programs for multiple myeloma?
What adverse events are reported with AMG 701 and how are they managed in clinical practice?
What are the potential combination therapies involving AMG 701 and other agents for multiple myeloma treatment?